$65 Million

Seres Therapeutics, Inc.

Follow-on Offering

Bookrunner, June 2019

Seres Therapeutics, Inc.
Seres Therapeutics is a microbiome therapeutics platform company developing a novel class of biological drugs. The Company is initially focused on implementing its platform to develop Ecobiotic microbiome therapeutics to treat dysbiosis in the colonic microbiome. The Company’s pipeline consists of four distinct product candidates: SER-287 and SER-301 for the treatment of ulcerative colitis, SER-109 for the treatment of recurrent C. difficile infection and SER-401 for use with checkpoint inhibitors in patients with solid tumors.